Current status of genetics in ALS and Tofersen: ID-ALS study and hardship program.

We would like to briefly update you on the current status (03/01/2023) of the ID-ALS02 study and the transition to the Tofersen Hardship Program After the successful completion of the first part

Successful completion of the ID-ALS study Part 1: genetic testing of 1.000 people with ALS in Germany

The first part of the ID-ALS study to identify genetic alterations in people with amyotrophic lateral sclerosis (ALS) was successfully completed by Ambulanzpartner on 30.10.2022. In the study

The ALS app supports the first genetic therapy for ALS with mutation in the SOD1 gene.

Since March 2022, two patients have been treated with the drug Tofersen at the ALS outpatient clinic of the Charité in Berlin. The documentation and monitoring of the course of treatment are